DXR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DX

Mkt Cap

$58.6M

Volume

4.46K

Loading chart

DX

DXRDaxor Corporation Common Stock

DXR

Pay with—

Available Balance0.00

DX

Mkt Cap

$58.7M

Volume

4.46K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in KansasDaxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas through its turnkey ezBVA Lab send-out model. The service provides 98% accurate blood volume measurements within 24 hours without requiring capital equipment, enabling clinicians to optimize decongestion strategies and reduce hospital readmissions.GlobeNewswire Inc. · Jul 30, 2026

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, TexasDaxor Corporation will exhibit its FDA-cleared Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference (July 9-12, 2026) in Texas. The company emphasizes how BVA provides objective plasma and red blood cell data to improve dysautonomia therapy, representing a shift from subjective symptom tracking to precision, data-driven diagnostics.GlobeNewswire Inc. · Jul 7, 2026

Daxor Corporation Announces $9 Million Registered Direct OfferingDaxor Corporation announced a definitive agreement to sell 765,958 shares of common stock at $11.75 per share to fundamental investors, raising approximately $9 million in gross proceeds. The offering is expected to close on January 26, 2026, with net proceeds intended for general corporate purposes and working capital. Lake Street Capital Markets is serving as the exclusive placement agent.GlobeNewswire Inc. · Jan 23, 2026

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth SummitDaxor Corporation will participate in the Maxim Growth Summit in New York City, presenting its innovative Blood Volume Analysis (BVA) technology to institutional investors and featuring one-on-one meetings with potential investors.GlobeNewswire Inc. · Oct 21, 2025

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025Daxor Corporation, a leader in blood volume measurement technology, will showcase its innovative Blood Volume Analysis (BVA) at the MedAxiom Cardiovascular Transforum Spring 2025 conference. WellStar Health System will present findings on how BVA-driven strategies significantly reduced kidney injury following LVAD implantation.GlobeNewswire Inc. · Apr 17, 2025

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and ExpoDaxor Corporation, the global leader in blood volume measurement technology, presented new data from Duke University at the American College of Cardiology's annual conference. The research reinforced the value of Daxor's blood volume analysis (BVA) technology in managing heart failure patients, highlighting its superiority over traditional pressure-based assessments.GlobeNewswire Inc. · Apr 2, 2025

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024Daxor Corporation, a leader in blood volume measurement technology, reported a strong financial performance in 2024, with a 116.5% increase in revenue and cash flow break-even in Q1 2025. The company also announced the imminent filing for its next-generation blood volume analyzer with the FDA.GlobeNewswire Inc. · Mar 4, 2025

Daxor to Exhibit at World's Largest Critical Care ConferenceDaxor Corporation, the global leader in blood volume measurement technology, will be exhibiting its innovative BVA-100 technology at the SCCM 2025 Critical Care Congress. The technology has demonstrated significant impact on patient outcomes, reducing mortality and hospital stays in critical care settings.GlobeNewswire Inc. · Feb 18, 2025

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales MomentumDaxor Corporation, the global leader in blood volume measurement technology, has expanded its ezBVA Lab service to two new health systems in Arizona and the Southwest region. The BVA platform is a critical diagnostic tool that provides real-time insights into a patient's volume status, enabling early detection of fluid imbalances and cardiovascular risks.GlobeNewswire Inc. · Dec 18, 2024

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024Daxor Corporation, a leader in blood volume measurement technology, will showcase its BVA technology at the HFSA Annual Scientific Meeting, highlighting its ability to personalize heart failure treatment and improve patient outcomes.GlobeNewswire Inc. · Sep 19, 2024

to start trading

DX

DXRDaxor Corporation Common Stock

DXR

Pay with—

Available Balance0.00

Your PositionYou don't own any DXR yet.

Related Tickers

Earnings